Board of Directors

>Board Committees

>Corporate Responsibility

Paul L. Berns, President and Chief Executive Officer, Allos Therapeutics, Inc.

Paul L. Berns has served as a member of our Board of Directors since June 2010. Since March 2006, he has served as the President and Chief Executive Officer, and as a member of the Board of Directors, of Allos Therapeutics, Inc. From June 2002 to July 2005, he was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company (acquired by Genzyme Corporation in 2005). From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals-Knoll, and from 1990 to 2000, he held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns serves on the board of XenoPort, Inc. He received a B.S. in Economics from the University of Wisconsin.

Samuel D. Colella, Managing Member, Versant Ventures

Samuel D. Colella has served as a member of our Board of Directors since 2003. Since 1999, he has served as Managing Director of Versant Ventures, a venture capital firm, which he co-founded. He serves on the boards of Genomic Health Inc., a molecular diagnostics company, Alexza Pharmaceuticals, a drug delivery company, and several privately-held companies. Mr. Colella received a B.S. from the University of Pittsburgh and an M.B.A. from the Stanford Graduate School of Business.

Bruce C. Cozadd, Chairman and Chief Executive Officer

Bruce C. Cozadd is a co-founder and has served as our Chairman and Chief Executive Officer since April 2009. From 2003 until 2009, he served as our Executive Chairman. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of Cerus Corporation, a biopharmaceutical company, Threshold Pharmaceuticals, a biotechnology company, and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.

Bryan C. Cressey, Partner, Cressey & Company LP

Bryan C. Cressey has served as a member of our Board of Directors since 2006. Since 2007 he has been a Partner of Cressey and Company, LLC, and since 1998, he has been a Partner of Thoma Cressey Bravo, Inc., both private equity firms of which he is a founder. Mr. Cressey serves on the boards of Belden, Inc., a networking cable technology company, Select Medical Corporation, a healthcare services company, and several privately-held healthcare services companies. He received a B.A. from the University of Washington, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School.

Patrick Enright, Managing Director, Longitude Capital

Patrick G. Enright has served as a member of our Board of Directors since July 2009. Since 2006, Mr. Enright has served as a Managing Member of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Mr. Enright also has significant life sciences operations experience, beginning his career more than 25 years ago at Sandoz (now Novartis). He currently serves on the boards of Corcept Therapeutics Incorporated, a pharmaceutical company, and several privately-held companies. Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Michael W. Michelson, Member, Kohlberg Kravis Roberts & Co. L.P.

Michael W. Michelson has served as a member of our Board of Directors since 2004. Since 1981, he has been employed by Kohlberg Kravis Roberts & Co. L.P., or KKR, where he is a Member and also serves on KKR’s Investment and Management Committees. Funds affiliated with KKR are our company’s largest stockholder. Mr. Michelson serves on the boards of HCA Inc., a healthcare services company and Biomet, Inc., a healthcare manufacturing company. He received an A.B. from Harvard College and a J.D. from Harvard Law School.

James C. Momtazee, Member, Kohlberg Kravis Roberts & Co. L.P.

James C. Momtazee has served as a member of our Board of Directors since 2004. Since 1996, he has been employed by KKR, where he is a Member. He serves on the boards of HCA Inc., a healthcare services company, and Accellent Inc., a manufacturing and engineering services company. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Robert M. Myers, President

Robert M. Myers is a co-founder and was appointed as our President in March 2007 and has served as a member of our Board of Directors since April 2009. From 2003 until 2007, he served as our Executive Vice President and Chief Business Officer. From 2002 until 2003, he served as Executive Vice President, Pharmaceuticals at Exelixis, a biotechnology company. He previously held various positions with ALZA Corporation from 1992 to 2001, most recently as its Senior Vice President, Commercial Development. In this role, he was responsible for ALZA Corporation’s corporate development, mergers and acquisitions, new product planning and corporate planning. He received B.S. and M.S. degrees from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Kenneth W. O'Keefe, Managing Director, Beecken Petty O'Keefe & Company

Kenneth W. O’Keefe has served as a member of our Board of Directors since 2004. Since 1997, he has been Managing Director of Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded; and funds affiliated with his firm are among our largest stockholders. He serves on the boards of several privately-held healthcare companies. He received a B.A. from Northwestern University and an M.B.A. from the University of Chicago.

Alan Sebulsky, Managing Partner, Apothecary Capital LLC

Alan M. Sebulsky has served as a member of our Board of Directors since 2004. Since 2003, he has served as a Managing Partner of Apothecary Capital LLC, an investment advisory firm. From 2002 to 2003, he was an independent investor. From 1994 to 2002, he held various positions, most recently as a Managing Director, at Lincoln Capital Management, a private investment management firm, where he was responsible for investments in the health care industry. He received a B.B.A. and an M.S. from the University of Wisconsin, Madison.

James B. Tananbaum, MD, Managing Director, Prospect Venture Partners

James B. Tananbaum, M.D. has served as a member of our Board of Directors since 2003. Since 2000, Dr. Tananbaum has been a Managing Director of Prospect Venture Partners, a venture capital firm he co-founded. He serves on the boards of Infinity Pharmaceuticals, Inc., and several privately-held companies. Dr. Tananbaum was the founder of GelTex, Inc. and Theravance, Inc. He received a B.S.E.E. from Yale University, and an M.D. and an M.B.A. from Harvard University.

Rick E Winningham, Chief Executive Officer, Theravance, Inc.

Rick E Winningham has served as a member of our Board of Directors since May 2010. Since 2001, he has served as the Chief Executive Officer and a member of the Board of Directors of Theravance, Inc., a biopharmaceutical company, and in April 2010, he was appointed Chairman of the Board of Directors. From 1997 to 2001, he served as the President of Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) and, from 2000 to 2001, as President of Global Marketing. He is a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University and holds a seat on the Advisory Council for the Keck Graduate Institute. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.

Nathaniel M. Zilkha, Director, Kohlberg Kravis Roberts & Co. L.P.

Nathaniel M. Zilkha has served as a member of our Board of Directors since October 2007. Since 2004, he has been employed by KKR, where he is the global co-head of Special Situations Investing at KKR, which includes the firm’s activities in public and private distressed and structured investments. Previously he was a member of KKR’s North American Private Equity team. Prior to joining KKR, Mr. Zilkha spent eight years in the Principal Investment Area of Goldman Sachs, where he invested in private equity and principal debt transactions. Mr. Zilkha graduated cum laude from Princeton University.